Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
"We continue to execute on expanding our menu of non-invasive and cost-effective biomarker tests," said
Precision medicine in oncology continues to evolve as the number of clinically validated biomarkers to determine treatment pathways for specific tumor types is growing. Genomic profiling has identified fusions of the NTRK gene, involving either NTRK1, NTRK2 or NTRK3, which encode for the protein receptors TRKA, TRKB and TRKC, respectively1. The presence of TRK proteins has been associated with more aggressive cancer in certain tumor types, such as lung cancer2. Currently, for qualified patients with NTRK fusions, there are two approved first-generation TRK inhibitor therapies on the market, Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib), which are associated with high clinical response rates (>75%)3. While the prevalence of NTRK fusions is low, they can be found across a broad range of tumor types, therefore testing patients for this family of biomarkers may be warranted4.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the potential clinical utility of our proprietary technology platform and our ability to increase adoption of our liquid biopsy platform in the oncology market, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
- A. Drilon, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 378:731-739, 2018.
- A. Lange, et al. Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers (
Basel) 2018 Apr; 10(4): 105.
- E. Coco, et al. NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy. Nat Rev
Clin Oncol15: 737-747, 2018. Matthew Stenger, Larotrectinib for Solid Tumors With NTRK Gene Fusions. The ASCO Post. Dec, 2018.
- J. Hechtman, et al. Pan-Trk Immunohistochemistry is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol. 2017 Nov; 41(11): 1547–1551.
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-the-launch-of-its-liquid-biopsy-test-to-detect-trk-biomarkers-in-the-blood-of-patients-diagnosed-with-cancer-300962772.html